



Sir—The report by Staffan Hägg and
colleagues (April l, p 1155)' about
venous thromboembolism and
clozapine, leads to the question whether
die increased incidence is either: specific
for this drug, a general property of
antipsychotic drugs, or associated with
the underlying condition. After the
discovery of the neuroleptic qualities of
chlorpromazine and its analogues in the
early 1950s, and their widespread
application, a higher incidence of
venous thromboembolism was
described in the German literature
between 1953 and 1977. Several studies
were of case series, but some contained
control groups. A comprehensive study
compared two groups of patients
between 1953 and 1963 (1172
Schizophrenie or depressive patients on
chlorpromazine, amitriptyline, or
imipramine vs 1172 psychiatric patients
who did not use neuroleptic or
antidepressant medication). The
frequency of thromboembolic
complications was 2-9% and 0-6%,
respectively.2 The report contains
multiple references to the contemporary
literature, among others a 1959 study by
Grahmann and colleagues, who found
11 cases of venous thrombosis among
338 phenothiazine users, versus only
one in a non-phenothiazine control
group. Ahistorical comparison by
Mahmodian, who found a three-fold
risk of venous thrombosis in 1958-61,
in comparison with 1915-22 in
psychiatric and neurology patients was
mentioned in a case series report.3
We rediscovered this literature, when
trying to undgrstand the findings of a
study of idiopathic pulmonary emboli
deaths. Of 14 000 necropsies at the
Leiden University Medical Center,
Leiden, The Netherlands, from 1970
until mid 1994, we found 27 patients
with idiopathic pulmonary embolism for
whom sufficient material was present
for further investigation; ten of these
necropsies were on psychiatric patients.4
This was an unexpectedly high number.
On doing further record searches, we
found that five of these patients used
neuroleptic drugs; of the non-users of
neuroleptic drugs, three had impaired
mobility. The necropsy findings and the
older literature prompted us to go back
to the records of a previous case-control
study,5 from that study inpatients had
been excluded (thus, psychiatric
inpatients had been excluded).
Nevertheless, four patients of 474
incident cases with a first episode of
deep-vein thrombosis had used
neuroleptic drugs, compared with none
of a similar number of controls.
Venous thrombosis seems to be
associated with the use of neuroleptic
drugs in psychiatric patients. It cannot
be excluded that the findings are an
expression of some other underlying
factor that could predispose to
thrombosis. Nevertheless, we conclude
that the association between venous
thrombosis and psychiatric illness is
worthy of renewed investigation, with
an emphasis on the effect of neuroleptic
drugs.
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Sir—From the twelve cases of
clozapine-associated venoüs thrombosis
and thromboembolism Staffan Hägg
and colleagues1 present, they conclude
that the assumed risk of
thromboembolism in clozapine-treated
patients is at least one per 2000-6000
Data were retrieved from the database
of the Swedish Adverse Reactions
Advisory Committee, which is based on
spontaneous reporting. This may be a
limitation of the study, äs was rightly
pointed out in the paper. Here, we
present data on clozapine-associated
thromboembolism in the Arzneimittel-
sicherheit in der Psychiatrie (AMSP)
project. This is a continuing surveillance
Programme of severe adverse drug
reactions (ADRs) in all inpatients of 35
psychiatric hospitals in Germany and
Switzerland.2 Data are collected by
specially instructed drug-monitors,
according to a detailed protocol. Results
are reviewed in regional and national
Conferences. Data concerning the
screened patient population are
compiled in the participating hospitals
on two reference days per year. In such
a setting, under-reporting of ADRs is
•less likely and more clinical information
of screened and affected patients is
available than in the setting described
by Hägg and colleagues.
A total of about 103000 inpatients
were surveyed from 1993 to 1999. Of
these 13 081 (12-7%) received
clozapine, 59 637 (57-9%) received
other neuroleptics, 30 282 (29-4%)
were not treated with neuroleptics.
There were five episodes (0-038%)
episodes of thromboembolism among
four patients treated with clozapine. In
patients treated with other neuroleptics,
there were 17 (0-029%) cases of
thromboembolism, in the group
without neuroleptic treatment there
were eight (0-026%) cases. There is no
significant difference between these
groups.
In our study, the frequency of
thromboembolism associated with
clozapine treatment is one in 2600
patients. This confirms the work by
Hägg and colleagues. However, the
incidence of thromboembolism in
patients treated with neuroleptics other
than clozapine or np neuroleptics was
not significantly different from that
in the clozapine group. So
thromboembolism may not be
clozapine-associated after all. Other risk
factors must be taken into account, such
äs reduced motor activity during
psychiatric illness. In databases relying
on spontaneous reporting, there may be
a bias towards reporting ADR in
clozapine-treated patients because of
the restricted use of that drug. Further
research is needed to identify
psychiatric patients at risk of developing
this potentially fatal complication.
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Sir—Staffan Hägg and colleagues1
summarised 12 cases of venous
thromboembolism associated with
clozapine treatment, that had been
submitted to the Swedish Adverse
Reactions Advisory Committee. Here
we summarise the US experience, based
on the spontaneous reporting System of
the Food and Drug Administration
(FDA). Current labelling of clozapine
in the USA mentions the adverse event
of pulmonary embolism in the
precautions section. Deep vein
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thrombosis (DVT) is mentioned in this
section äs well äs in the postmarketing
clinical experience section.
Between February, 1990, when
clozapine was first marketed in the USA,
and December, 1999, the FDA received
99 unduplicated, domestic reports
of venous thromboembolism (83
mentioned puknonary embolism with or
without DVT, and 16 mentioned DVT
alone). 63 (64%) reports described
deaths äs a result of pulmonary
embolism; 32 were confirmed by
necropsy. Of 36 non-fatal cases, only
seven had been documented objectively
by such diagnostic techniques äs
perfusion-ventilation lung scanning and
venography. Thus, 39 (39%) of the
99 reports had objective evidence of
pulmonary embolism or DVT.
The median age for the 39 individuals
was 38 (ränge 17-70) years. 20 (51%)
were females. The median daily dose
was 400 (ränge 12-5-900) mg. The
median duration of clozapine exposure
before diagnosis was 3 months (ränge 2
days to 6 years). Information on risk
factors for puknonary embolism and
DVT varied by report; however 18 of 39
patients were described äs obese. The
reporting rate for fatal puknonary
embok'sm in the cohort described above
is consistent with that described in the
labelling for clozapine in the USA.
Hägg and colleagues concluded that
the actual risk of venous thrombo-
embolism in clozapine-treated patients
with schizophrenia is probably higher
than their estimate, because of under-
reporting. Under-reporting, however,
may not be äs substantial in the USA
because of the medical attention these
patients receive, resulting from the
requirement for weekly white-blood-cell
counts to be done.
Detection of venous thrombo-
embolism in patients with schizophrenia
is clinically challenging. For many
reasons, these patients may have
difficulty communicating the typical
Symptoms of DVT and pulmonary
embolism. Maintaining a high index
of suspicion for the possibility of
venous thromboembok'sm in patients
on clozapine may promote earlier
diagnosis and appropriate Intervention.
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MRI and the second French
case of vCJD
Sir—Martin Zeidler and colleagues
(April 22)' have described a bilaterally
increased pulvinar signal on T2-
weighted magnetic resonance imaging
(MRI) of patients from the UK with
variant Creutzfeldt-Jakob disease2
(vCJD). Here, we reporr similar routine
MRI features in a French patient with
vCJD. We also present a description of
diffusion-weighted imaging (DWI) in
vCJD.
A woman aged 36 years presented
with emotional and behavioural changes
associated with severe depression. The
Psychiatrie signs worsened despite u^e of
antidepressive drugs, and were folloVed
by progressive dementia, unsteadiness of
gait, and cerebellar and pyramidal signs.
7 months after onset, she also deyeloped
drowsiness, progressive immobility,
unresponsiveness, involuntary move-
ments, and myoclonus. Cerebrospinal
fluid examination (including the dosage
of 14-3-3 protein) was normal. The
electroencephalogram showed bilateral
aperiodic slow waves.
Brain MRI done 7 months after
Symptom onset led to the diagnosis of
suspected CJD. Fluid attenuated
Inversion recovery (FLAIR) images
showed bilateral and Symmetrie high
signal changes observed equally in the
caudate nuclei, and putamen. Pulvinar
high signal accompanied by increased
signal in the dorsomedial thalamic
nuclei gave the so-called hockey-stick
appearance, bilaterally (figure; top). On
DWI (not shown), striking hypersignal
with decreased values of the apparent
diffusion coefficient (ADC) were seen
bilaterally in the striatum (75% of
normal), while only slight hypersignal,
with skghtly increased ADC values, was
observed in the thalami (116% of
normal).
The patient died 14 months after
disease onset and the family gave
consent for a necropsy to be
done. Neuropathological examination
disclosed spongiform changes, diffuse
astrogliosis, and numerous florid plaques
immunolabelled with monoclonal
antibody (figure; bottom). Western-blot
analysis showed the presence of type 4
proteinase K resistant PrP, confirming
this diagnosis of vCJD.
This constitutes the second French
case of vCJD. The patient had never
travelled abroad, therefore confirming
that continental European and UK
vCJD share similar clinical,
histopathological, and neuroimaging
features.3 Our findings confirm those of
Zeidler and colleagues, and extend to
non-UK patients the potential
usefulness of detecting an increased
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Top: FLAIR MRI showing bilateral
increased signal in the caudate nuclei
and in the putamen (asterisks), and the
pulvinar and the dorsomedial thalamic
nuclei (arrowheads)
Bottom: Two florid plaques
immunolabelled with monoclonal
antibody directed to PrP
Arrows point to the PrP-positive core,
arrowheads point to the spongiform changes.
pulvinar signal for the diagnosis of
vCJD. The DWI pattern of vCJD was
correlated with the known pathological
data. We observed slightly increased
ADC values in the pulvinar and low
ADC values in the striatum. Low ADC
values in CJD are presumably a result of
spongiform cellular changes,4 which, on
pathological examination of brains
affected by vCJD are seen to pre-
dominate in the striatum. Conversely,
neuropathological evidence of gliosis
and neuronal loss with moderate
spongiform changes in the pulvinar are
consistent with increased ADC values in
the pulvinar.
The relevance of MRI findings in
patients with vCJD is highlighted by the
results of DWI, which closely parallel
the pattern of abnormal tissue seen
histologically. The widespread use
of MRI in patients with persistent
early psychiatric features despite
appropriate psychiatric treatment could
provide a valuable source of
epidemiological data on the emerging
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